KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBT: 2010-2025

Historic EBT for Novavax (NVAX) over the last 16 years, with Sep 2025 value amounting to -$203.0 million.

  • Novavax's EBT fell 65.97% to -$203.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $350.7 million, marking a year-over-year increase of 225.36%. This contributed to the annual value of -$176.6 million for FY2024, which is 67.48% up from last year.
  • Novavax's EBT amounted to -$203.0 million in Q3 2025, which was down 288.95% from $107.5 million recorded in Q2 2025.
  • In the past 5 years, Novavax's EBT ranged from a high of $519.8 million in Q1 2025 and a low of -$829.7 million during Q4 2021.
  • Moreover, its 3-year median value for EBT was -$122.3 million (2024), whereas its average is -$26.9 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 1,890.58% in 2021, then soared by 457.80% in 2025.
  • Novavax's EBT (Quarterly) stood at -$829.7 million in 2021, then soared by 77.76% to -$184.5 million in 2022, then increased by 4.23% to -$176.7 million in 2023, then surged by 58.36% to -$73.6 million in 2024, then tumbled by 65.97% to -$203.0 million in 2025.
  • Its EBT was -$203.0 million in Q3 2025, compared to $107.5 million in Q2 2025 and $519.8 million in Q1 2025.